The assessment of non‐inferiority in a gold standard design with censored, exponentially distributed endpoints
暂无分享,去创建一个
Matthias Mielke | A. Munk | A. Schacht | M. Mielke | A Munk | A Schacht
[1] G. Freitag,et al. Methods for Assessing Noninferiority with Censored Data , 2005, Biometrical journal. Biometrische Zeitschrift.
[2] Meinhard Kieser,et al. Planning and analysis of three-arm non-inferiority trials with binary endpoints. , 2007, Statistics in medicine.
[3] Armin Koch,et al. Hypothesis Testing in the “Gold Standard” Design for Proving the Efficacy of an Experimental Treatment Relative to Placebo and a Reference , 2004, Journal of biopharmaceutical statistics.
[4] T. Schwartz,et al. A two‐stage sample size recalculation procedure for placebo‐ and active‐controlled non‐inferiority trials , 2006, Statistics in medicine.
[5] Sue-Jane Wang,et al. A Regulatory Perspective on Choice of Margin and Statistical Inference Issue in Non‐inferiority Trials , 2005, Biometrical journal. Biometrische Zeitschrift.
[6] S S Ellenberg,et al. Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues , 2000, Annals of Internal Medicine.
[7] Armin Koch,et al. Discussion on “Establishing Efficacy of a New Experimental Treatment in the ‘Gold Standard’ Design” , 2005 .
[8] S. Lange,et al. Choice of delta: requirements and reality--results of a systematic review. , 2005, Biometrical journal. Biometrische Zeitschrift.
[9] R. Dworkin,et al. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain , 2005, Neurology.
[10] Man-Lai Tang,et al. Tests of Noninferiority via Rate Difference for Three-Arm Clinical Trials with Placebo , 2004, Journal of biopharmaceutical statistics.
[11] MD N. Canas,et al. Reversible cervical hydromyelia in subacute combined degeneration , 2005, Neurology.
[12] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[13] J A Lewis,et al. Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.
[14] A. Zangen,et al. Screening for new antidepressants with fast onset and long‐lasting action , 2000 .
[15] Eric R. Ziegel,et al. Statistical Issues in Drug Development , 1997 .
[16] R. Sysko,et al. Placebo response in studies of major depression: variable, substantial, and growing. , 2002, JAMA.
[17] Iris Pigeot,et al. Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. , 2003, Statistics in medicine.
[18] R. D'Agostino,et al. Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.
[19] J Röhmel,et al. Therapeutic equivalence investigations: statistical considerations. , 1998, Statistics in medicine.
[20] A. Nierenberg,et al. Evolution of remission as the new standard in the treatment of depression. , 1999, The Journal of clinical psychiatry.
[21] Mark Rothmann,et al. Design and analysis of non‐inferiority mortality trials in oncology , 2002, Statistics in medicine.